Skip to main content
Premium Trial:

Request an Annual Quote

ATCC, Qiagen Ink Bioinformatics Partnership

NEW YORK – Nonprofit biological resource and standards organization ATCC said on Monday that it will provide Qiagen with sequencing data from its collection of animal and human cell lines and biological materials.

Under the agreement, Qiagen Digital Insights (QDI), the bioinformatics business of Qiagen, will establish a database from this information to help QDI customers in the biotechnology and pharmaceutical industries discover new disease pathways and therapeutic targets, Manassas, Virginia-based ATCC said.

ATCC will initially produce transcriptome and whole-exome sequencing datasets from the most highly utilized human and animal cell lines in its collection. These datasets will include multiple biological and technical replicates that will help establish a baseline for a wide range of cell lines under typical cell culture conditions. Users eventually will also be able to request specific datasets for inclusion in the database.

"Our expertise in bioinformatics software and services, combined with ATCC's sequencing data, will further expand our genomics knowledge and OmicSoft Land databases, thus empowering scientists from around the world with actionable insights into the discovery and development of precision therapeutics," Jonathan Sheldon, senior VP and head of QDI, said in a statement. 

"This first-of-its-kind arrangement will allow ATCC to provide data provenance that is traceable, standardized, and authenticated to its original source," Raymond Cypess, chairman and CEO of ATCC, said in a statement.